119 related articles for article (PubMed ID: 36516643)
1. The statuses of HER2 expression and mismatch repair in endometrial clear cell carcinoma.
Bayramoglu Z; Erozbek SY; Ozdemir IA; Ulker V; Muezzinoglu B
Pathol Res Pract; 2023 Jan; 241():154258. PubMed ID: 36516643
[TBL] [Abstract][Full Text] [Related]
2. HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma.
Cagaanan A; Stelter B; Vu N; Rhode EN; Stewart T; Hui P; Buza N; Al-Niaimi A; Flynn C; Weisman PS; McGregor SM
Int J Gynecol Pathol; 2022 Mar; 41(2):132-141. PubMed ID: 33782344
[TBL] [Abstract][Full Text] [Related]
3. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
4. Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma.
Sukov WR; Zhou J; Geiersbach KB; Keeney GL; Carter JM; Schoolmeester JK
Hum Pathol; 2023 Jul; 137():94-101. PubMed ID: 37094656
[TBL] [Abstract][Full Text] [Related]
5. Endometrial Serous Carcinoma With Clear-Cell Change: Frequency and Immunohistochemical Analysis.
Hariri N; Qarmali M; Fadare O
Int J Surg Pathol; 2018 Apr; 26(2):126-134. PubMed ID: 28954565
[TBL] [Abstract][Full Text] [Related]
6. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome.
Nelson GS; Pink A; Lee S; Han G; Morris D; Ogilvie T; Duggan MA; Köbel M
Gynecol Oncol; 2013 Nov; 131(2):309-14. PubMed ID: 23938375
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India.
Rekhi B; Menon S; Deodhar KK; Ghosh J; Chopra S; Maheshwari A
Ann Diagn Pathol; 2020 Aug; 47():151558. PubMed ID: 32619922
[TBL] [Abstract][Full Text] [Related]
8. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
Alkushi A; Köbel M; Kalloger SE; Gilks CB
Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
[TBL] [Abstract][Full Text] [Related]
9. Targeted mutation analysis of endometrial clear cell carcinoma.
Hoang LN; McConechy MK; Meng B; McIntyre JB; Ewanowich C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2015 Apr; 66(5):664-74. PubMed ID: 25308272
[TBL] [Abstract][Full Text] [Related]
10. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of HNF1β, Napsin A and P504S/Alpha-Methylacyl-CoA Racemase (AMACR) as markers of endometrial clear cell carcinoma.
Travaglino A; Raffone A; Arciuolo D; Santoro A; Inzani F; Di Maio A; Visiello U; Fulgione C; Guida M; Mollo A; Insabato L; Zannoni GF
Pathol Res Pract; 2022 Sep; 237():154019. PubMed ID: 35907281
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
13. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility.
Fadare O; Desouki MM; Gwin K; Hanley KZ; Jarboe EA; Liang SX; Quick CM; Zheng W; Parkash V; Hecht JL
Am J Surg Pathol; 2014 Feb; 38(2):189-96. PubMed ID: 24145649
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
[TBL] [Abstract][Full Text] [Related]
15. Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases.
Zannoni GF; Santoro A; Angelico G; Spadola S; Arciuolo D; Valente M; Inzani F; Pettinato A; Vatrano S; Fanfani F; Scambia G; Fraggetta F
Hum Pathol; 2019 Oct; 92():10-17. PubMed ID: 31269413
[TBL] [Abstract][Full Text] [Related]
16. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA
Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcome and Morphology-Based Analysis of p53 Aberrant and Mismatch Repair Protein-Deficient Ovarian Clear Cell Carcinoma and Their Association With p16, HER2, and PD-L1 Expression.
Wilkins R; Lin LH; Xia R; Shiomi T; Zamuco RD; Shukla PS
Am J Clin Pathol; 2023 Nov; 160(5):466-476. PubMed ID: 37415414
[TBL] [Abstract][Full Text] [Related]
18. The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma.
Ye S; Zhou S; Zhong S; Shan B; Jiang W; Yang W; Cai X; Yang H
BMC Cancer; 2022 Apr; 22(1):449. PubMed ID: 35461222
[TBL] [Abstract][Full Text] [Related]
19. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
20. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers.
Ramalingam P; Masand RP; Euscher ED; Malpica A
Int J Gynecol Pathol; 2016 Sep; 35(5):410-8. PubMed ID: 26598976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
